Dave Fornell, DAIC Editor

Dave Fornell, editor of DAIC Magazine

Blog | Dave Fornell, DAIC Editor | Heart Valve Technology| April 05, 2016

Wow! — My Single Word Summary of TAVR Data at ACC 2016

TAVR, Sapien 3, ACC.16

There has been a lot of conjecture that transcatheter aortic valve replacement (TAVR) may one day replace open-heart surgical aortic valve replacement (SAVR). However, after attending the American College of Cardiology (ACC) 2016 meeting, it is evident that change will come much sooner than anyone anticipated. “Wow” is really the key summary I can offer regarding the TAVR vs. SAVR data presented at ACC. Three key presentations were all positive for TAVR, showing it is at least equal or superior to surgery. This is not bad for a new technology with largely inexperienced operators being able to perform as well or better than cardiac surgeons with decades of experience.

The Partner 2A trial for the Sapien XT showed that the second-generation TAVR device was equal to surgery in intermediate-risk surgical patients. It was pointed out by experts in numerous ACC sessions that if the two techniques are equal, the minimally invasive method will usually win out as a new standard of care. 

The improved Sapien 3 device replaced the XT toward the end of the Partner 2 trial. The valve has a fabric skirt that significantly reduces paravalvular leak, which was an issue with the earlier XT and the original versions of the Sapien. The PARTNER results were separated for the XT and Sapien 3 arms of the study. The data for Sapien 3 show it performed better than surgery in intermediate patients. 

Watch a video interview with Vinod Thourani, M.D on the Sapien 3 beating surgery.

U.S. CoreValve pivotal trial results showed TAVR was better than surgery, and the three-year results presented at ACC show a continued positive trend. The lines between TAVR and surgery for all-cause mortality also continue to diverge in favor of TAVR. 

Watch a video interview with Michael Reardon, M.D., co-principal investigator for the CoreValve trial.

Stoke rate have been high with TAVR compared to surgery in earlier trials, but that rate has dropped in recent trials presented at ACC.16 to now be equal with surgery. 

Watch a video interview with Chandan Devireddy, M.D. at ACC.16 explaining the drop in TAVR stroke rates. 

Cardiothoracic surgeon Steven Bolling, M.D., University of Michigan, said TAVR is a brand new technology being implanted by new, inexperienced operators. But, within five years of the technology gaining U.S. market approval, it has beaten out the performance of very specialized, experienced surgeons. He noted that new interventional cardiology operators were able to show better patient outcomes with TAVR than his own surgical outcomes, and he has the experience of performing more than 5,000 surgical valve procedures. Bolling said if a test between two competing technologies shows them to be at least equal, the easiest one to use will always be the ultimate winner. He said there is little doubt in his mind that TAVR will become the standard of care in the next few years.

The three main questions standing in the way of full acceptance of TAVR as a new standard of care are: 1. How it performs in low-risk patients; 2. Durability; and 3. Its ability to gain reimbursement. The U.S. Food and Drug Administration (FDA) gave the green light earlier this year for low-risk patient trials for both the CoreValve and Sapien 3. The results of those trials in a couple years will be very highly anticipated. The long-term durability of TAVR valves will also be assessed in these patients over the next decade.  

Long-term durability data has been hard to track in the extreme- and high-risk patients included in the early PARTNER and CoreValve trials due to high mortality rates. So, this data is expected from the intermediate- and low-risk patient studies, but this will require seven to 10 years of data before a clear picture of durability emerges. 

Reimbursement is still an issue, especially with the average cost of TAVR being several thousand dollars more than surgery. However, the cost of the devices and of the procedures will go down as TAVR’s usage expands, the experts say, as with any new technology. The current cost-conscious healthcare environment will also likely embrace TAVR as the cost drops, especially as this minimally invasive technique increasingly becomes a same-day outpatient procedure.

Related Content

Aspirin Lowers Risk of Death for Patients with Diabetes, Heart Failure
News | ACC | March 15, 2018
March 15, 2018 — For people living with both Type 2 diabetes and heart failure, taking an...
ECG on Smartwatch Accurately Detects AFib
News | ACC | March 15, 2018
March 15, 2018 – A newly-designed wristband and corresponding app that works with a smartwatch can accurately display
Breastfeeding May Have Long-Term Heart Health Benefits for Some Moms
News | ACC | March 15, 2018
March 15, 2018 — Women with norm
Alirocumab Reduces Cardiovascular Events after Acute Coronary Syndrome
News | ACC | March 13, 2018
March 13, 2018 –  Among patients with persistently high cholesterol despite high-intensity statin therapy, the propro
Wearable Defibrillator Cuts Overall Mortality, But Not Sudden Deaths After Heart Attack

Jeffrey Olgin, M.D., F.A.C.C., Division of Cardiology, UCSF

On behalf of VEST investigators 

News | ACC | March 13, 2018
March 13, 2018 –  Wearing a lightweight vest equipped with a cardioverter...
ACC 2018 highlights and trends.  #acc.18, #ACC, #ACC2018
Feature | ACC | January 31, 2018
The rapid pace of change continues to be a hallmark in cardiovascular medicine and many see that pace accelerating.
ACC 2018 Late-Breaking Trials Announced
News | ACC | January 23, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Videos | ACC | April 03, 2017
DAIC Editor Dave Fornell takes a tour of some of the interesting new technologies from the vendor booths on the expo
Overlay Init